<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36863925</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>41 Suppl 1</Volume><Issue>Suppl 1</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>06</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020.</ArticleTitle><Pagination><StartPage>A25</StartPage><EndPage>A34</EndPage><MedlinePgn>A25-A34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2023.02.060</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(23)00214-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Trivalent oral poliovirus vaccine (tOPV) was globally replaced with bivalent oral poliovirus vaccine (bOPV) in April 2016 ("the switch"). Many outbreaks of paralytic poliomyelitis associated with type 2 circulating vaccine-derived poliovirus (cVDPV2) have been reported since this time. The Global Polio Eradication Initiative (GPEI) developed standard operating procedures (SOPs) to guide countries experiencing cVDPV2 outbreaks to implement timely and effective outbreak response (OBR). To assess the possible role of compliance with SOPs in successfully stopping cVDPV2 outbreaks, we analyzed data on critical timelines in the OBR process.</AbstractText><AbstractText Label="METHODS">Data were collected on all cVDPV2 outbreaks detected for the period April 1, 2016 and December 31, 2020 and all outbreak responses to those outbreaks between April 1, 2016 and December 31, 2021. We conducted secondary data analysis using the GPEI Polio Information System database, records from the U.S. Centers for Disease Control and Prevention Polio Laboratory, and meeting minutes of the monovalent OPV2 (mOPV2) Advisory Group. Date of notification of circulating virus was defined as Day 0 for this analysis. Extracted process variables were compared with indicators in the GPEI SOP version 3.1.</AbstractText><AbstractText Label="RESULTS">One hundred and eleven cVDPV2 outbreaks resulting from 67 distinct cVDPV2 emergences were reported during April 1, 2016-December 31, 2020, affecting 34 countries across four World Health Organization Regions. Out of 65 OBRs with the first large-scale campaign (R1) conducted after Day 0, only 12 (18.5%) R1s were conducted by the target of 28 days after Day 0. Of the 89 OBRs with the second large-scale campaign (R2) conducted after Day 0, 30 (33.7%) R2s were conducted by the target of 56 days after Day 0. Twenty-three (31.9%) of the 72 outbreaks with isolates dated after Day 0 were stopped within the 120-day target.</AbstractText><AbstractText Label="CONCLUSION">Since "the switch", delays in OBR implementation were evident in many countries, which may be related to the persistence of cVDPV2 outbreaks &gt;120 days. To achieve timely and effective response, countries should follow GPEI OBR guidelines.</AbstractText><CopyrightInformation>Copyright © 2023. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Darwar</LastName><ForeName>Roopa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: rdarwar@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biya</LastName><ForeName>Oladayo</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: ybn2@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>Sharon A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: SGreene@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jorba</LastName><ForeName>Jaume</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: jfj6@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Safadi</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Polio Eradication Department, World Health Organization, Geneva, Switzerland. Electronic address: alsafadim@who.int.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franka</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: rpf5@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiesen</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: ejw2@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durry</LastName><ForeName>Elias</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: exd4@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallansch</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: map1@cdc.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="N">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060740" MajorTopicYN="N">Disease Eradication</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Circulating vaccine-derived poliovirus</Keyword><Keyword MajorTopicYN="N">Oral polio vaccine</Keyword><Keyword MajorTopicYN="N">Polio eradication</Keyword><Keyword MajorTopicYN="N">Polio outbreak response</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>2</Day><Hour>22</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36863925</ArticleId><ArticleId IdType="mid">NIHMS1911484</ArticleId><ArticleId IdType="pmc">PMC10354706</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2023.02.060</ArticleId><ArticleId IdType="pii">S0264-410X(23)00214-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hampton LM, Farrell M, Ramirez-Gonzalez A, Menning L, Shendale S, Lewis I, Rubin J, Garon J, Harris J, Hyde T, Wassilak S, Patel M, Nandy R, Chang-Blanc D, Immunization Systems Management Group of the Global Polio Eradication Initiative. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine — Worldwide, 2016. Morbidity and Mortality Weekly Report, 2016; 65(35): 934–938. https://www.jstor.org/stable/24858956.</Citation><ArticleIdList><ArticleId IdType="pubmed">27606675</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkowska D.A., Pallansch M.A., Cochi S.L., Kovacs S.D., Wassilak S.G., Thompson K.M. Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart. Risk Anal. 2021;41(2):320–328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7814395</ArticleId><ArticleId IdType="pubmed">32632925</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns C.C., Diop O.M., Sutter R.W., Kew O.M. Vaccine-derived polioviruses. J Infect Dis. 2014;210(suppl_1):S283–S293.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316847</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorba J., Diop O.M., Iber J., Henderson E., Zhao K., Quddus A., et al. Update on vaccine-derived poliovirus outbreaks—worldwide, January 2018–June 2019. Morb Mortal Wkly Rep. 2019;68(45):1024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6855511</ArticleId><ArticleId IdType="pubmed">31725706</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Standard operating procedures: responding to a poliovirus event or outbreak – version 4; 2020. p. 25. Retrieved from https://apps.who.int/iris/handle/10665/363627.</Citation></Reference><Reference><Citation>Lopalco P.L. Wild and vaccine-derived poliovirus circulation, and implications for polio eradication. Epidemiol Infect. 2017;145(3):413–419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9507676</ArticleId><ArticleId IdType="pubmed">27866483</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G.R., O’Reilly K.M., Grassly N.C., Edmunds W.J., Mach O., Krishnan R.S.G., et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science. 2020;368(6489):401–405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10805349</ArticleId><ArticleId IdType="pubmed">32193361</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. International Health Regulations (2005), 2nd ed.; 2008. Retrieved from http://www.who.int/ihr/publications/9789241596664/en.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative Polio Information System. SIA data dictionary; 2020. Retrieved from https://extranet.who.int/polis/DocumentsComponent/GetDocument?fileId=593.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. nOPV2: clinical development summary; 2020. Retrieved from https://polioeradication.org/wp-content/uploads/2021/02/nOPV2-Clinical-Development-Summary-1.29-EN.pdf.</Citation></Reference><Reference><Citation>World Health Organization. First ever vaccine listed under WHO emergency use; 2020. Retrieved from https://www.who.int/news/item/13-11-2020-first-ever-vaccine-listed-under-who-emergency-use.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. Call to action to support COVID-19 response; 2020. Retrieved from https://polioeradication.org/wp-content/uploads/2020/04/POB-COVID-19-Statement-20200402.pdf.</Citation></Reference><Reference><Citation>Thompson K.M., Pallansch M.A., Duintjer Tebbens R.J., Wassilak S.G., Kim J.H., Cochi S.L. Preeradication vaccine policy options for poliovirus infection and disease control. Risk Anal. 2013;33(4):516–543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7941951</ArticleId><ArticleId IdType="pubmed">23461599</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>